Xellia Pharmaceuticals becomes member of Medicines for Europe

pharmafile | January 21, 2021 | News story | |  Europe, xellia 

Xellia Pharmaceuticals, a manufacturer of specialty anti-infective treatments, has become a member of Medicines for Europe.

Medicines for Europe represents the generic, biosimilar and value-added pharmaceutical industries in Europe. Member companies are responsible for providing the essential medicines that European patients, healthcare professionals and healthcare systems rely on.

Generic, biosimilar and value-added medicines currently account for 70% of essential medicines prescribed in Europe, and are needed daily to help patients manage acute and chronic diseases such as cancer, auto-immune, and respiratory conditions. Off-patent and repurposed medicines are also a key part of the COVID-19 response, facilitating patient treatment in hospital emergency units globally.

Xellia is a leading supplier of critical established anti-infective drugs for serious bacterial and antibiotic-resistant infections and fungal diseases. Although active pharmaceutical ingredient manufacturing is the Danish company’s focus, Xellia has also invested significantly in R&D to create an innovative pipeline of value-added, anti-infective medicines intended to enhance patient care.

Carl-Åke Carlsson, CEO and President of Xellia Pharmaceuticals, said: “At Xellia, we have patient needs at the center of all our efforts. We focus on supplying consistently through our global vertical integration strategy and by improving supply security through multiple sources of in-house production of our APIs and drug products. We hold great pride in that our products are affordable and accessible globally.

“Acceptance into Medicines for Europe is great recognition of our work and will enable Xellia to unite with likeminded companies also working to secure access to quality medicines for patients in Europe. Better access to the most effective therapies means millions more patients will receive the treatments they need, providing long-term benefits for society. This is well aligned with Xellia’s purpose to save and enhance lives by leading the fight against infections.”

Adrian van den Hoven, Director General of Medicines for Europe, also commented: “Medicines for Europe is excited to have Xellia join industry-wide efforts to increase access to effective medicines, improve security of supply and engage on critical public health issues such as anti-microbial resistance. Generic and value-added medicines development are critical to tackling these public health challenges.”

Darcy Jimenez

Related Content

EC approves combination treatment for kidney cancer

The European Commission (EC) has approved Ipsen’s Cabometyx in combination with Opdivo as a first-line …


Janssen’s esketamine nasal spray gets Europe approval for new indication

The European Commission (EC) has authorised the expanded use of Janssen’s Spravato (esketamine nasal spray), co-administered …

European approval for Kite’s CAR-T therapy Tecartus in elapsed or refractory mantle cell lymphoma

Gilead-owned Kite Therapeutics has secured marketing authorisation from the European Commission for its chimeric antigen …

Latest content